3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
142
Stomach Neoplasms
104
Carcinoma, Non-Small-Cell Lung
87
Pancreatic Neoplasms
81
Carcinoma, Hepatocellular
74
Melanoma
59
Esophageal Neoplasms
57
Ovarian Neoplasms
50
Squamous Cell Carcinoma of Head and Neck
49
Parkinson Disease 4, Autosomal Dominant Lewy Body
44
Neoplasms
43
Carcinoma, Renal Cell
43
Triple Negative Breast Neoplasms
39
Neoplasm Metastasis
37
Lung Neoplasms
36
Breast Neoplasms
36
Uterine Cervical Neoplasms
35
Cholangiocarcinoma
35
Esophageal Squamous Cell Carcinoma
33
Head and Neck Neoplasms
29
Endometrial Neoplasms
29
Biliary Tract Neoplasms
26
Carcinoma, Transitional Cell
25
Urinary Bladder Neoplasms
23
Colonic Neoplasms
23
Small Cell Lung Carcinoma
20
Prostatic Neoplasms
17
Liver Neoplasms
17
Adenocarcinoma Of Esophagus
15
Adenocarcinoma
15
Interventions
3-fluoro-2-(4-((2-nitro-1H-imidazol-1-yl)methyl)-1H-1,2,3-triazol-1-yl)propan-1-ol
4
pimonidazole
2
TH 302
2
pembrolizumab
1
inositol trispyrophosphate
1
gadobutrol
1
fluoromisonidazole
1
Tirapazamine
1
Surgical Procedures, Operative
1
Radiotherapy
1
Propofol
1
Pancreaticoduodenectomy
1
Paclitaxel
1
Ipilimumab
1
Injections
1
Gemcitabine
1
Ethiodized Oil
1
Cisplatin
1
Blood Specimen Collection
1
Biopsy
1
AQ4N
1
4-methylbenzenesulfonic acid
1
3-(4-(2-fluoroethoxy)phenyl)-2-(3-methyl-2-(4-((2-sulfamoylbenzo(d)thiazol-6-yloxy)methyl)-1H-1,2,3-triazol-1-yl)butanamido)propanoic acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hypoxia
×
pembrolizumab
×
Gastrointestinal
×
Clear all
NCT05281003
2023-07-13
HYPERION
Fudan University
Phase 2
Recruiting
128 enrolled